Top Stories
The blood-based assay is designed to detect multiple cancers and pinpoint where they may have originated, potentially helping guide follow-up investigations.
Sava is targeting CE approval for a sensor that could guide insulin dosing without routine fingerstick checks.
The drugmaker said it tested Chai's models across a panel of diverse targets and saw designs with "strong binding affinities."
At the midpoint of its proposed offering, Iambic would raise $150 million.
The series D comes less than a month after the Italian company secured €17 million ($19.1 million) in funding.
Conference News
HOUSTON, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics, a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic services, today announced it wi...
New data from a European trial suggest that vision restored by a chip placed beneath the retina can last.11-Oct-2026 at 12:55 PM EDT, by American Academy of Ophthalmology (AAO)Newswise — People with g...
– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention –– Overall detection of colore...
RadiusXR and Topcon Healthcare, Inc. unveil InspirePRO at AAO: the full measurement range expertly engineered into a lightweight wearable experience.Purpose-built medical-grade perimeter combines comp...
Posters explore whether HelioLiver™ Dx can flag hepatocellular carcinoma when ultrasound is negative, imaging is indeterminate, or a tumor is not yet visibleSAN ANTONIO, Oct. 9, 2026 /PRNewswire/ -- H...
